China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
China's Jiangsu Hengrui Pharmaceuticals said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to develop 13 early‑stage oncology, hematology and immunology programmes, with potential milestone payments of up to $15.2 billion.
Open original source